HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer

An abstract presented during the 2023 ASCO Annual Meeting provided information on the phase 3 HER2CLIMB-05 trial, which is currently enrolling. The trial will analyze progression-free survival associated with the addition of tucatinib to first-line standard of care trastuzumab/pertuzumab as maintenance therapy for patients with metastatic HER2-positive breast cancer.